Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2015

View Archived Issues

Serina initiates phase I trial of SER-214 in patients with Parkinson's disease

Valor initiates first-in-human study of IGN-002 for NHL

Rovalpituzumab tesirine from Stemcentrx receives FDA orphan drug designation

Identification of CSF biomarkers for atypical parkinsonian syndromes

Novel preclinical model for cancer cachexia

Agios Pharmaceuticals starts phase I trial of pyruvate kinase deficiency candidate

Bayer plans phase I trial of BAY-1251152 in patients with advanced cancers

Aimmune Therapeutics moves peanut allergy therapeutic AR-101 into phase III

City of Hope discloses SENP inhibitors that prevent HIV genome integration

Amarantus requests rare pediatric disease and orphan drug designations

ADCT-402 shows antitumor activity against CD19-expressing B-cell malignancies

Midatech Pharma completes acquisition of Zuplenz

Vitae initiates proof-of-concept study of VTP-38543 in atopic dermatitis

Novel reversible bromodomain inhibitor shows promise for AML

Novel BET bromodomain inhibitor from Epigenetix a potential clinical candidate

Entospletinib is well tolerated in iNHL patients

Nanjing Sanhome Pharmaceutical patents EGFR inhibitors

French scientists describe GPBAR1 agonists

Kyoto Pharmaceutical Industries reports napabucasin prodrugs

Bristol-Myers Squibb presents nAChR alpha7 agonists

Adamed develops p53-MDM2 interaction inhibitors

Takeda Pharmaceutical divulges muscarinic M1 PAMs

Shionogi reports development of antifungal agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...